Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Kamphuis E, Boesjes CM, Loman L, Bakker DS, Poelhekken M, Zuithoff NPA, Kamsteeg M, Romeijn GLE, van Wijk F, de Bruin-Weller MS, de Graaf M, Schuttelaar MLA. Kamphuis E, et al. Among authors: schuttelaar mla. Pediatr Allergy Immunol. 2022 Dec;33(12):e13887. doi: 10.1111/pai.13887. Pediatr Allergy Immunol. 2022. PMID: 36564878 Free PMC article.
Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema.
Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: schuttelaar mla. JAMA Dermatol. 2018 Aug 1;154(8):969-970. doi: 10.1001/jamadermatol.2018.2027. JAMA Dermatol. 2018. PMID: 29971331 No abstract available.
[Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN, Oosterhaven JAF, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Voorberg AN, et al. Among authors: schuttelaar mla. Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227. Ned Tijdschr Geneeskd. 2019. PMID: 30945835 Dutch.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: schuttelaar mla. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: schuttelaar mla. Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31. Allergy. 2020. PMID: 31593343
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Spekhorst LS, et al. Among authors: schuttelaar mla. Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. Allergy. 2020. PMID: 32302412 Free PMC article. No abstract available.
Hyperkeratotic hand eczema: Eczema or not?
Politiek K, Loman L, Pas HH, Diercks GFH, Lemmink HH, Jan SZ, van den Akker PC, Bolling MC, Schuttelaar MLA. Politiek K, et al. Among authors: schuttelaar mla. Contact Dermatitis. 2020 Sep;83(3):196-205. doi: 10.1111/cod.13572. Epub 2020 Jun 1. Contact Dermatitis. 2020. PMID: 32333380 Free PMC article.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: schuttelaar mla. J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
178 results